Next Article in Journal
Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Previous Article in Journal
Back to Basics: Choosing the Appropriate Surface Disinfectant
Previous Article in Special Issue
An Antisense yycF RNA Modulates Biofilm Organization of Methicillin-Resistant Staphylococcus aureus and Pathogenicity in a Rat Model of Osteomyelitis

New Quinone Antibiotics against Methicillin-Resistant S. aureus

Drug Development Laboratory, Faculty of Chemical and Pharmaceutical, Sciences, Universidad de Chile, Sergio Livingstone 1007, Santiago 8380492, Chile
Facultad de Medicina y Ciencia, Universidad San Sebastián, Lago Panguipulli 1390, Puerto Montt 5501842, Chile
Agents of Bacterial Meningitis Laboratory, Instituto de Salud Pública de Chile, Santiago 7780050, Chile
Laboratorio de Investigación en Agentes Antibacterianos (LIAA), Departamento de Microbiología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción 4070386, Chile
Millennium Initiative for Collaborative Research on Bacterial Resistance (MICROB-R), Av. Las Condes 12.438, Lo Barnechea, Región Metropolitana, Santiago 8320000, Chile
Centro de Investigación Biomédica, Facultad de Medicina y Ciencias, Universidad San Sebastián, Sede de la Patagonia, Lago Panguipulli 1390, Puerto Montt 5501842, Chile
Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, 1340 Jefferson Park Ave., Charlottesville, VA 22908, USA
Authors to whom correspondence should be addressed.
Academic Editor: Marc Maresca
Antibiotics 2021, 10(6), 614;
Received: 14 March 2021 / Revised: 10 May 2021 / Accepted: 18 May 2021 / Published: 21 May 2021
(This article belongs to the Special Issue Antibiotic Resistance and Treatment of MRSA Infection)
There is an urgent need for the development of new antibiotics. Here, we describe the inhibitory activity of new quinone compounds against methicillin-resistant Staphylococcus aureus (ATCC® 43300), methicillin-sensitive S. aureus (ATCC® 29213), and two clinical isolates from Chile (ISP-213 and ISP-214). We observed 99.9% reduction in viability within 2 h of exposure without the cultures exhibiting any post-antibiotic effect, which was twice the kinetics to that observed with vancomycin. These clinical isolates did not acquire resistance to these quinone derivatives during the course of our study. We found that these compounds protected larvae of the greater wax moth, sp. Galleria mellonella, from infection by these MRSA clinical strains as effectively as vancomycin. These quinone derivatives are potential drug candidates worth further development. View Full-Text
Keywords: methicillin-resistant S. aureus (MRSA); drug discovery; quinone-antibiotics methicillin-resistant S. aureus (MRSA); drug discovery; quinone-antibiotics
Show Figures

Figure 1

MDPI and ACS Style

Campanini-Salinas, J.; Andrades-Lagos, J.; Hinojosa, N.; Moreno, F.; Alarcón, P.; González-Rocha, G.; Burbulis, I.E.; Vásquez-Velásquez, D. New Quinone Antibiotics against Methicillin-Resistant S. aureus. Antibiotics 2021, 10, 614.

AMA Style

Campanini-Salinas J, Andrades-Lagos J, Hinojosa N, Moreno F, Alarcón P, González-Rocha G, Burbulis IE, Vásquez-Velásquez D. New Quinone Antibiotics against Methicillin-Resistant S. aureus. Antibiotics. 2021; 10(6):614.

Chicago/Turabian Style

Campanini-Salinas, Javier, Juan Andrades-Lagos, Nicolás Hinojosa, Fabián Moreno, Pedro Alarcón, Gerardo González-Rocha, Ian E. Burbulis, and David Vásquez-Velásquez. 2021. "New Quinone Antibiotics against Methicillin-Resistant S. aureus" Antibiotics 10, no. 6: 614.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop